BioLingus biolingus.ch


The BioLingus technology has been developed over many years. The focus is to allow "biological drugs", which are almost all administered by injection, to be administered in an oral (sublingual) tablet. The technology is mature and can be applied to peptides, proteins and vaccines. Proof of concept is available for each of these types of molecules. Our initial key therapeutic focus for internal development is diabetes (patients take injections daily over their lifetime) and inflammatory dis...Show all

The BioLingus technology has been developed over many years. The focus is to allow "biological drugs", which are almost all administered by injection, to be administered in an oral (sublingual) tablet. The technology is mature and can be applied to...Show all

Company (Alive / Active)

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
BioLingus $0M Nov 15, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related BioLingus Jobs

jobs by Indeed job
						search
There is no Investors data available for this company. Please select another tab.
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Method for treating inflammatory conditions with mucosally administered interleukin-2 Nov 09, 2011 Mar 22, 2016 Patent